Though considered a rare disease, CIDP affects between 1 to 7 adults per 100,000 and approximately 1 in 200,000 children, with many experts suspecting underdiagnosis and misdiagnosis still plague ...

Trump and I have something in common. We’ve both been thinking about why the judiciary has held firm when many other American institutions (especially conservative institutions) have collapsed.

Chronic inflammatory neuropathies include multifocal motor neuropathy, which is purely motor and often associated with complement-fixing antibodies to ganglioside GM1, paraproteinaemic demyelinating ...

There’s no test to tell you if you have chronic inflammatory demyelinating polyneuropathy (CIDP). Its symptoms are similar to Guillain-Barre syndrome, but unlike GBS, those symptoms. If you’ve ...

The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month this May by launching a global campaign to ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long-term neurological disorder that targets your body’s nerves. Anyone can get CIDP, but it’s most common in older adults and ...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...

VYVGART is the first IgG Fc-antibody fragment targeting CIDP and marks the first CIDP treatment with a novel mechanism of action in more than 30 years, if approved. The treatment is designed for ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation. Get ...

CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from.

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada. TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased ...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.